deferoxamine has been researched along with Syndrome in 15 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage." | 6.53 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016) |
| "Evidence has emerged over the last several years indicating that aluminum accumulation in patients with chronic renal failure can cause certain forms of renal osteodystrophy, in particular osteomalacia and an aplastic lesion." | 4.77 | Aluminum and renal osteodystrophy. ( Coburn, JW; Nebeker, HG, 1986) |
| " It is also the second case report of a Pearson patient suffering from severe iron overload and liver disease that responded to therapy with deferoxamine." | 3.74 | Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene. ( Augoustides-Savvopoulou, P; Farmaki, E; Karatza, E; Kefala-Agoropoulou, K; Lazaridou, A; Roilides, E; Tsantali, H; Tsiouris, J, 2007) |
| " Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage." | 2.53 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016) |
| " In the United States, deferiprone has been approved for three times daily dosing since 2011 and has recently gained approval for twice-daily administration." | 1.91 | An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. ( Badawy, SM; Shah, A; Shah, R, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (60.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, R | 1 |
| Shah, A | 1 |
| Badawy, SM | 1 |
| Kontoghiorghe, CN | 1 |
| Kontoghiorghes, GJ | 1 |
| Taher, AT | 1 |
| Porter, JB | 1 |
| Kattamis, A | 1 |
| Viprakasit, V | 1 |
| Cappellini, MD | 1 |
| Kefala-Agoropoulou, K | 1 |
| Roilides, E | 1 |
| Lazaridou, A | 1 |
| Karatza, E | 1 |
| Farmaki, E | 1 |
| Tsantali, H | 1 |
| Augoustides-Savvopoulou, P | 1 |
| Tsiouris, J | 1 |
| Bottomley, SS | 1 |
| Ambruso, DR | 1 |
| Mahony, BS | 1 |
| Githens, JH | 1 |
| Rhoades, ED | 1 |
| Chekanov, VS | 1 |
| Nikolaychik, V | 1 |
| O'Brien, RT | 1 |
| Graziano, JH | 1 |
| Arnold, H | 1 |
| Wehinger, H | 1 |
| Deus, B | 1 |
| Löhr, GW | 1 |
| Forget, BG | 1 |
| Nathan, DG | 1 |
| Cacciola, E | 1 |
| Nebeker, HG | 1 |
| Coburn, JW | 1 |
| Rovelli, E | 1 |
| Luciani, L | 1 |
| Pagani, C | 1 |
| Albonico, C | 1 |
| Colleoni, N | 1 |
| D'Amico, G | 1 |
| Vadász, G | 1 |
6 reviews available for deferoxamine and Syndrome
| Article | Year |
|---|---|
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; | 2016 |
Sideroblastic anaemia.
Topics: 5-Aminolevulinate Synthetase; Adult; Anemia, Sideroblastic; Blood Transfusion; Bone Marrow; Chloramp | 1982 |
Iron overload: clinical and pathologic aspects in pediatrics.
Topics: Abnormalities, Multiple; Adolescent; Adult; Ascorbic Acid Deficiency; Bloodletting; Child; Child, Pr | 1977 |
Iron metabolism and chelation therapy in hemosiderosis.
Topics: Ascorbic Acid; Blood Transfusion; Chelating Agents; Deferoxamine; Diet; Gentisates; Hemochromatosis; | 1978 |
Thalassemia.
Topics: Blood Transfusion; Bone Marrow Examination; Deferoxamine; Diagnosis, Differential; Erythrocyte Count | 1975 |
Aluminum and renal osteodystrophy.
Topics: 24,25-Dihydroxyvitamin D 3; Aluminum; Animals; Bone and Bones; Calcitriol; Caseins; Chronic Kidney D | 1986 |
9 other studies available for deferoxamine and Syndrome
| Article | Year |
|---|---|
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overloa | 2023 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating | 2016 |
Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene.
Topics: Anemia, Sideroblastic; Deferoxamine; Fatal Outcome; Female; Hemochromatosis; Hemochromatosis Protein | 2007 |
Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
Topics: Administration, Oral; Anemia, Aplastic; Ascorbic Acid; Blood Transfusion; Child; Chromosome Aberrati | 1982 |
Iron contributes to endothelial dysfunction in acute ischemic syndromes.
Topics: Acute Disease; Coronary Circulation; Coronary Disease; Deferoxamine; Endothelial Growth Factors; End | 2002 |
[Controlled desferrioxamine treatment of congenital anaemia and transfusion siderosis (author's transl)].
Topics: Adolescent; Anemia, Aplastic; Child; Deferoxamine; Erythrocytes, Abnormal; Humans; Iron; Male; Sider | 1978 |
[Dyserythropoietic syndromes: incidence, diagnosis, therapy].
Topics: Anemia, Dyserythropoietic, Congenital; Anemia, Refractory; Anemia, Sideroblastic; Deferoxamine; Diag | 1990 |
Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids.
Topics: Aluminum; Brain Diseases; Deferoxamine; Electroencephalography; Female; Humans; Male; Middle Aged; N | 1988 |
[A case of Diamond-Blackfan anemia: Experiences of 10-year follow-up study].
Topics: Adolescent; Anemia, Aplastic; Biopsy; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Eryt | 1974 |